Ann Lab Med.  2018 Mar;38(2):169-171. 10.3343/alm.2018.38.2.169.

A Novel e8a2BCR-ABL1 Fusion Transcript without Insertion Sequence in a Patient with Chronic Myeloid Leukemia

• Jin C
• Zhu X
• Xiao M
• Liu S
• Liu X
• Liu J
• Xu X
• Yi S
• Meng L

• KMID: 2403364
• DOI: http://doi.org/10.3343/alm.2018.38.2.169

Abstract

No abstract available.

MeSH Terms

Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*

Figure

• 

  Fig. 1 The diagnosis and monitoring of CML. (A) Conventional karyotype analysis by G-banding showing typical translocation between chromosome 9 and 22 (arrows). (B) FISH analysis using BCR-ABL dual fusion probe. BCR-ABL-positive cells (red arrow), normal cells (green arrow). (C) Sanger sequencing of the nested RT-PCR product demonstrating the direct junction between BCR exon e8 and ABL exon a2 (reference sequence: BCR, NM_004327.3; ABL1, NM_005157.5). (D) Clinical response to treatment monitored by FISH.

Reference

1. Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, KanagalShamanna R, et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016; 127:1269–1275. PMID: 26729897.

2. Demehri S, Paschka P, Schultheis B, Lange T, Koizumi T, Sugimoto T, et al. e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants? Leukemia. 2005; 19:681–684. PMID: 15703785.

3. Tchirkov A, Couderc JL, Périssel B, Goumy C, Regnier A, Uhrhammer N, et al. Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript. Leukemia. 2006; 20:167–168. PMID: 16270035.

4. Riva E, Manrique Arechavaleta G, De Almeida C, Costa V, Fernandez Del Campo M, Ifran González S, et al. A novel e8a2 BCR-ABL1 fusion with insertion of MAST2 exon 2 in a four-way translocation t (1;17;9;22) (p35;q24;q44;q11) in a patient with chronic myeloid leukemia. Leuk Lymphoma. 2016; 57:203–205. PMID: 25899399.

5. Reid AG, Nacheva EP. A potential role for PRDM12 in the pathogenesis of chronic myeloid leukaemia with derivative chromosome 9 deletion. Leukemia. 2004; 18:178–180. PMID: 14523459.

6. Huet S, Dulucq S, Chauveau A, Ménard A, Chomel JC, Maisonneuve H, et al. Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts. Genes Chromosomes Cancer. 2015; 54:595–605. PMID: 26252834.

7. Chen L, Wu Y, You Y, Xiao M, Yao Y, Li W. A novel e8a2 BCR-ABL1 intronic fusion through insertion of a chromosome 22 BCR gene fragment into chromosome 9 in an atypical Philadelphia (Ph) chromosome chronic myeloid leukemia patient. Leuk Lymphoma. 2016; 57:2930–2933. PMID: 27118564.

8. Cayuela JM, Rousselot P, Nicolini F, Espinouse D, Ollagnier C, Bui-Thi MH, et al. Identification of a rare e8a2BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib. Leukemia. 2005; 19:2234–2236.

9. Qin YZ, Jiang B, Jiang Q, Zhang Y, Jiang H, Li JL, et al. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant. Acta Haematol. 2008; 120:146–149. PMID: 19039205.

10. Park IJ, Lim YA, Lee WG, Park JS, Kim HC, Lee HJ, et al. A case of chronic myelogenous leukemia with e8a2 fusion transcript. Cancer Genet Cytogenet. 2008; 185:106–108. PMID: 18722880.